A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India

NCT05855967 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis
Psoriatic Arthritis

Interventions

DRUG: Ixekizumab

Sponsor

Eli Lilly and Company